ClinicalTrials.gg
Not yet recruitingNCT07082634Updated Jul 24, 2025

Immediate Implant Placement Using the Socket Shield Technique in Maxillary Esthetic Zone

An interventional study of Socket shield concept and immediate implant placement in Socket Shield Technique and Maxillary Esthetic Zone, sponsored by Hams Hamed Abdelrahman. Not yet recruiting at 1 site in Lebanon. Open to participants aged 18 Years to 40 Years. Per ClinicalTrials.gov, last updated 2025-07-24.

Sponsored by Hams Hamed Abdelrahman · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Jun 2026, 5 months ago, but the record still lists the study as not yet recruiting.
Phase
Not applicable
Study type
Interventional
Enrollment
8
Allocation
Not applicable
Ages
18 Years to 40 Years
Sex
All
01

Study summary

Immediate implant placement in the esthetic zone is an approach that helps preserve soft and hard tissue architecture. However, post extraction bone resorption is still a significant challenge. The socket shield technique (SST) has emerged as a promising way for preserving the buccal plate, potentially improving implant stability and reducing radiographic bone loss. The aim of the present study is to evaluate the clinical and radiographic outcomes of the socket shield technique in the maxillary esthetic zone by assessing implant stability, radiographic bone loss as well as esthetic outcome over a specified follow-up period.

02

Conditions studied

  • Socket Shield Technique
  • Maxillary Esthetic Zone
03

In context

Lead sponsor

Hams Hamed Abdelrahman is the lead sponsor of 111 studies on the registry; 9 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with a non-restorable maxillary tooth in the aesthetic zone indicated for extraction and subsequent immediate implant placement.
  • Patients with extraction socket Type I.
  • A good standard of oral hygiene.

Exclusion criteria

Exclusion Criteria:

  • Patients with extraction socket Type II or III, with defect in the buccal plate.
  • Absence of at least 2 mm bone apical to the extraction socket, necessary to obtain adequate primary stability for the implant assessed by pre-operative radiographic evaluation.
  • The presence of any local factor that may interfere with extraction as tooth ankylosis.
  • Patients with deciduous teeth.
  • Patients with bruxism
  • Heavy smokers.
  • Systemic conditions that are considered as a for placement of implant or those that may interfere with wound healing and conditions and uncontrolled diseases.
  • History of oral or intravenous bisphosphonate therapy or any treatments with other medications that may interfere with bone metabolism within the past 12 months.
  • Patients receiving radiotherapy or chemotheraphy.
  • Patient with active infection or chronic infection with severe bone loss.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
8 participants (estimated)

Study arms

  • Experimental
    Socket shield and immediate implant

    Procedure: Socket shield concept and immediate implant placement

Interventions

  • ProcedureSocket shield concept and immediate implant placement

    Tooth Sectioning: The tooth will be sectioned mesiodistally using a fissure bur, preserving the buccal segment. Palatal fragment extraction: carefully after sectioning the tooth , the palatal fragment is luxated and extracted with the most important factor is taking care of the buccal part not to become loose , the extraction is done using a periotome to be minimally invasive and to preserve the bone from major damage. Shield Preparation: The buccal fragment is reduced to bone level using a round bur, a beveled edge is created using a diamond football bur, and the shield is thinned to maintain structural integrity. Implant Site Preparation: Sequential osteotomy performed under copious irrigation, ensuring primary stability. Implant Placement: A Megagen implant is inserted

06

What researchers measure

Primary outcomes

  1. Change in pain scores

    Pain will be evaluated, using visual analogue scale (VAS) as follows: (0-1= None, 2-4= Mild, 5-7= Moderate, 8-10= Severe) (Figure 1)

    Time frame: baseline, 7, 14, and 21 days

  2. Change in implant stability

    The base line primary Implant Stability Quotient (ISQ) will be measured at the time of implant placement, while the secondary stability quotient will be measured after 6months during the prosthetic phase preparation.

    Time frame: baseline and 6 months

Secondary outcomes

  1. Change in post operative healing

    The wound healing will be assessed based on Landry Wound Healing Index. The Landry Index uses a numerical score based on the assessment of four given parameters (Erythema., Edema, Wound Margin Adaptation, and Presence of Exudate). Each parameter is given a score depending on its severity, and the total score determine an overall evaluation of wound healing

    Time frame: baseline, 7, 14, and 21 days

  2. change in crestal alveolar process width

    The width of the crestal alveolar process will be assessed by determination of the dimensional changes of Bucco-palatal ridge in the 6 months' scan. Measurements will be taken from the preoperative records and compared to those taken in the 6 month ones.

    Time frame: baseline and 6 months

  3. change in labial bone thickness

    the assessment of the thickness labial plate of bone in the scan performed after 6 months and comparing it with the preoperative CBCT scans.

    Time frame: baseline and 6 months

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Sep 2025; primary completion for Jun 2026, 9 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 15, 2025
First posted
Jul 24, 2025
StartEst.
Sep 1, 2025
Primary completionEst.
Jun 1, 2026
CompletionEst.
Jun 1, 2026
Last update
Jul 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07082634
Responsible party
Hams Hamed Abdelrahman (Lecturer of Dental Public Health and biostatistical consultanat, Alexandria University) — Sponsor-investigator
First posted
Jul 24, 2025
Start date
Sep 1, 2025 (estimated)
Primary completion
Jun 1, 2026 (estimated)
Completion
Jun 1, 2026 (estimated)
Last update
Jul 24, 2025

Study contacts

Mohamed M Issa, BDS
Contact
mohamadmarwanissa@gmail.com
+961 76 476 204

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion